Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 33,106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 3 Interventional Results available

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

NCT02573324
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414
Drug · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
68
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

NCT05059223
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
47
States / cities
Alabaster, Alabama • Peoria, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

NCT01199523
View directory record Official record
Conditions
Healthy Subjects
Interventions
Placebo, mirabegron, moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 28, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

X-82 to Treat Age-related Macular Degeneration

NCT02348359
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD, Macular Degeneration, Age-related, 10, Eye Diseases, Retinal Degeneration, Retinal Diseases
Interventions
X-82, Anti-VEGF, Placebo
Drug
Lead sponsor
Tyrogenex
Industry
Eligibility
50 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Tucson, Arizona • Beverly Hills, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Results available

Ultrasound-guided Adductor Canal Block for Total Knee Replacement

NCT02100579
View directory record Official record
Conditions
Complications; Arthroplasty, Knee Injuries
Interventions
Bupivacaine, Preservative free normal saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

NCT01644188
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

NCT02315703
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Plaque Removal Efficacy of a U-Shaped Sonic Power Toothbrush in Children

NCT06300073
View directory record Official record
Conditions
Dental Plaque
Interventions
Experimental: U-shaped Power Toothbrush, Placebo Comparator: Soft Manual Toothbrush
Device
Lead sponsor
Lander Enterprises, LLC
Industry
Eligibility
5 Years to 8 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 28, 2026, 5:57 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

GnRH Agonist at Embryo Transfer: IVF Outcomes

NCT03544073
View directory record Official record
Conditions
Infertility, Infertility, Female, Infertility, Male
Interventions
Saline Solution for Injection, Leuprolide Acetate
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 28, 2026, 5:57 AM EDT
Not listed Phase 2 Interventional

Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

NCT00174525
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-001
Drug
Lead sponsor
Pharmacology Research Institute
Other
Eligibility
50 Years to 85 Years
Timeline
2005 – 2008
U.S. locations
2
States / cities
Los Alamitos, California • Northridge, California
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

NCT03905525
View directory record Official record
Conditions
Sjögren Syndrome
Interventions
CFZ533, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions
CC-90001, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 2 Interventional

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

NCT05623189
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
43
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 28, 2026, 5:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

NCT05842174
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Hydroxychloroquine, Lipiodol, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 28, 2026, 5:57 AM EDT
Completed No phase listed Observational

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

NCT00545610
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Not listed
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 81 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT01457924
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ofatumumab 3mg, Ofatumumab 30mg, Ofatumumab 60mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Cullman, Alabama • Fullerton, California • Fairfield, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Minocycline Study in Pancreatic Cancer Patients

NCT01693523
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Minocycline, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 28, 2026, 5:57 AM EDT
Not yet recruiting Phase 2 Interventional

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

NCT05794659
View directory record Official record
Conditions
Advanced Ovarian Cancer
Interventions
AST-201, Paclitaxel, Carboplatin, Placebo, rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)
Biological · Drug
Lead sponsor
Aston Sci. Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 5:57 AM EDT
Not listed Phase 4 Interventional

Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)

NCT01830959
View directory record Official record
Conditions
Sarcoidosis
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 28, 2026, 5:57 AM EDT
Withdrawn Phase 2 Interventional

Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study

NCT02090296
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Hydroxyurea, Placebo
Drug · Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Months to 12 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00738062
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 28, 2026, 5:57 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories

NCT00239746
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Ibuprofen, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
59 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 4 Interventional

Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip

NCT00868088
View directory record Official record
Conditions
Actinic Cheilitis, Squamous Cell Carcinoma In-situ (SCC-is), Squamous Cell Carcinoma (SCC), Photodynamic Therapy (PDT), Mohs Surgery
Interventions
PDT prior to Mohs surgery
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 28, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Crossover Trial of AD036 in Obstructive Sleep Apnea

NCT04445688
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD036, Atomoxetine, Placebo
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Little Rock, Arkansas • Santa Ana, California • Chevy Chase, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 28, 2026, 5:57 AM EDT